SRRK

Scholar Rock Holding Corp. (SRRK) - Q2 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026. Scholar Rock is a global biopharmaceutical company focused on developing monoclonal antibodies for rare neuromuscular diseases, primarily Spinal Muscular Atrophy (SMA). The company has no commercial product revenue and relies on equity and debt financing to fund operations. As of June 30, 2026, the company had 121.6 million shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Debt Restructuring: In February 2026, the company terminated its previous loan agreement with Oxford Finance and entered a new Financing Agreement with Blue Owl Capital. The company drew $200 million in term loans under the new facility (up from $100 million outstanding under the prior facility at year-end 2025). This resulted in a $3.3 million loss on extinguishment of debt recorded in the first half of 2026.
• Equity Financing: The company generated $160.8 million in net proceeds from the sale of common stock under its At-The-Market (ATM) program during the six months ended June 30, 2026.
• Expense Trends:
  • Research & Development (R&D): Decreased slightly by 0.9% YTD ($110.0M vs $111.1M), driven by lower external costs for completed trials (SAPPHIRE, EMBRAZE, DRAGON), partially offset by increased internal costs and new trials (OPAL, FORGE).
  • General & Administrative (G&A): Increased significantly by 29.1% YTD ($100.9M vs $78.1M), primarily due to investments in commercial infrastructure, increased headcount, and professional fees.
• Liquidity: Total cash, cash equivalents, and marketable securities increased by $124.5 million compared to December 31, 2025, due to debt proceeds and ATM sales.

Guidance, Outlook, and Risks

• Regulatory Status (Apitegromab): The company resubmitted its Biologics License Application (BLA) to the FDA in March 2026 after receiving a Complete Response Letter (CRL) in September 2025 related to a third-party fill-finish facility inspection. The FDA accepted the resubmission with a PDUFA action date of September 30, 2026. The CRL did not cite efficacy or safety concerns.
• Commercialization: The company is actively building commercial infrastructure in anticipation of a potential launch in the U.S. and Europe upon approval.
• Pipeline Updates:
  • FSHD: Initiated Phase 2 FORGE trial in Q2 2026.
  • SMA (Pediatric): Ongoing Phase 2 OPAL trial for patients under two years of age.
  • SRK-439: Phase 1 study in healthy volunteers is underway; topline data expected in H2 2026.
• Liquidity Outlook: Management expects existing cash and marketable securities ($492.1 million) to fund operations into the second half of 2027. However, additional capital will be required to complete clinical development and commercialization.
• Risk Factors: Key risks include the uncertainty of FDA approval by the September 2026 deadline, reliance on third-party manufacturers (including the previously cited facility), and the need for future capital raises which may result in dilution.

Investor Verification Checklist

• Regulatory Timeline: Verify the status of the FDA review and the September 30, 2026 PDUFA date for apitegromab.
• Debt Covenants: Review the specific covenants in the new Blue Owl financing agreement, particularly the requirement to maintain a minimum unrestricted cash balance of 60% of outstanding principal.
• Manufacturing Resolution: Confirm the resolution of the FDA "Official Action Indicated" (OAI) classification for the third-party fill-finish facility and the status of the second facility included in the resubmission.
• Burn Rate: Monitor the quarterly cash burn rate against the projected runway into late 2027, especially given the increased G&A spending for commercial build-out.
• ATM Activity: Track future equity sales under the ATM program, as this impacts shareholder dilution.